Original Articles
Vol. 61 No. 1 (2009)
https://doi.org/10.4081/reumatismo.2009.21

Blocking TNF in vitro with infliximab determines the inhibition of expansion and interferon gamma production of Vγ9/Vδ2 T lymphocytes from patients with active rheumatoid arthritis. A role in the susceptibility to tuberculosis?

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
1625
Views
1280
Downloads

Authors

A.R. Giardina
office@pagepress.org
, Italy.
A. Accardo-Palumbo
, Italy.
F. Ciccia
, Italy.
A. Ferrante
, Italy.
A. Principato
, Italy.
R. Impastato
, Italy.
G. Triolo
, Italy.
Biological therapeutic agents neutralising tumour necrosis factor (TNF) are highly active in treating chronic inflammatory diseases, such as Crohn’s disease, rheumatoid arthritis, ankylosing spondylitis, uveitis, and psoriasis (1-3). From the beginning, side effects of TNF neutralisation - mostly infectious complications - were recognized, the most important being, however, pulmonary tuberculosis infections (4).

Downloads

Download data is not yet available.

How to Cite



1.
Blocking TNF in vitro with infliximab determines the inhibition of expansion and interferon gamma production of Vγ9/Vδ2 T lymphocytes from patients with active rheumatoid arthritis. A role in the susceptibility to tuberculosis? Reumatismo [Internet]. 2009 Mar. 30 [cited 2026 Sep. 12];61(1):21-6. Available from: https://www.reumatismo.org/reuma/article/view/reumatismo.2009.21

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.